Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis

K Daniels; P B van der Nat; S T F M Frequin; P J van der Wees; D H Biesma; E L J Hoogervorst; E M W van de Garde

doi:10.1155/2020/5463451

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis

Mult Scler Int. 2020 Jun 15:2020:5463451. doi: 10.1155/2020/5463451. eCollection 2020.

Authors

K Daniels^{1

2}, P B van der Nat^{1

2}, S T F M Frequin³, P J van der Wees², D H Biesma^{1

4}, E L J Hoogervorst³, E M W van de Garde^{5

6}

Affiliations

¹ Department of Value-Based Healthcare, St. Antonius Hospital, Utrecht/Nieuwegein, Netherlands.
² Radboud University Medical Center, Radboud Institute for Health Sciences, Scientific Center for Quality of Healthcare (IQ healthcare), Netherlands.
³ Department of Neurology, St. Antonius Hospital, Utrecht/Nieuwegein, Netherlands.
⁴ Department of Internal Medicine, University Medical Centre Utrecht, Utrecht, Netherlands.
⁵ Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, Netherlands.
⁶ Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht University, Utrecht, Netherlands.

Abstract

Background: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.

Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.

Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).

Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.

Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.